DBV Technologies | DBVT - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
DBV Technologies USD 13.4M 8.14M 2026-03
Galectin Therapeutics USD 1.48M 110K 2024-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Insmed USD 247.47M 208K 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 206.7M 50.1M 2026-06